(RTTNews) - Teva Pharmaceuticals USA is recalling specific lots of various strengths of FENTANYL Buccal Tablets CII to the consumer level citing a labeling error, the U.S. Food and Drug Administration ...

HONOLULU, HI—Patientswith chronic, noncancer-related pain who received fentanyl buccal tablet had consistent short-term efficacy acrossclinically meaningful analgesia measures, according to results of ...

A labeling problem has forced Teva to recall 13 lots of fentanyl buccal tablets. Safety updates on the product insert were omitted, leaving the possibility of misuse that “could lead to ...

Background and objectives: Patients with cancer, particularly those undergoing chemotherapy or radiotherapy, may develop oral mucositis. This is the first study to investigate the absorption profile ...

Credit: Teva Pharmaceuticals. Teva Pharmaceuticals is recalling certain lots of Fentanyl Buccal Tablets CII because safety updates were omitted in the product insert/medication guide. Teva ...

AUSTIN, TX—In a study presented at the American Pain Society’s 30th Annual Scientific Meeting, fentanyl buccal tablet (FBT) was shown to be more effective than traditional short-acting opioids (SAO) ...

Management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Opioid-tolerant patients are those ...

This phase I, multicentre, open-label study was conducted in the US between April and September 2005. The two participating centres obtained Institutional Review Board approval and all patients ...